Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 Oct;151(4):1123–1130.

Classical Hodgkin's disease. Clinical impact of the immunophenotype.

R von Wasielewski 1, M Mengel 1, R Fischer 1, M L Hansmann 1, K Hübner 1, J Franklin 1, H Tesch 1, U Paulus 1, M Werner 1, V Diehl 1, A Georgii 1
PMCID: PMC1858022  PMID: 9327746

Abstract

Antibodies against CD15, -30, and -20 are often used to support morphological diagnosis of Hodgkin's Disease (HD). The classical HD, i.e., the non-lymphocyte-predominance types, are CD15+, CD30+, and CD20- in general. However, the results for CD15 are less clear-cut in many studies, showing up to 40% of classical HD that lack positivity for this maker. Little is currently known about the relevance of antigen expression in relation to clinical outcome in HD. Therefore, the three markers were analyzed in 1751 cases from the German Hodgkin Study Group, using micro-wave epitope retrieval to optimize staining sensitivity. Eighty-three percent of the cases showed a classical immunophenotype (CD15+, CD30+, CD20-), twelve percent lacked CD15 positivity (CD15-, CD30+, CD20-), and five percent showed other combinations. For 1286 cases, clinical follow-up was available, which revealed significant differences for freedom from treatment failure (P = 0.0022) and overall survival (P = 0.0001) between cases with classical immunophenotype and CD15 negativity (CD30+, CD20-). Multivariate Cox regression using the three markers, age, sex, histology, stage, B-symptoms (fever, sweats, weight loss > 10% of body weight), hemoglobin, and erythrocyte sedimentation rate as factors showed that lack of CD15 expression in classical HD is an independent negative prognostic factor for relapses (P = 0.022) and survival (P = 0.0035). In conclusion, immunohistochemistry is able to identify classical HD cases with unfavorable clinical outcome.

Full text

PDF
1123

Images in this article

1128Figure 5
on p.1128
1128Figure 6
on p.1128

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnarsson B. A., Kadin M. E. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissues. Cancer. 1989 Jun 1;63(11):2083–2087. doi: 10.1002/1097-0142(19890601)63:11<2083::aid-cncr2820631102>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  2. Angel C. A., Warford A., Day S. J., Lauder I. Comparative quality assessment in immunocytochemistry: pilot study of CD15 staining in paraffin wax embedded tissue in Hodgkin's disease. J Clin Pathol. 1989 Oct;42(10):1096–1100. doi: 10.1136/jcp.42.10.1096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ashton-Key M., Thorpe P. A., Allen J. P., Isaacson P. G. Follicular Hodgkin's disease. Am J Surg Pathol. 1995 Nov;19(11):1294–1299. [PubMed] [Google Scholar]
  4. Axiotis C. A., Jennings T. A. Observations on bronchiolo-alveolar carcinomas with special emphasis on localized lesions. A clinicopathological, ultrastructural, and immunohistochemical study of 11 cases. Am J Surg Pathol. 1988 Dec;12(12):918–931. doi: 10.1097/00000478-198812000-00003. [DOI] [PubMed] [Google Scholar]
  5. Bishop P. W., Harris M., Smith A. P., Elsam K. J. Immunophenotypic study of lymphocyte predominance Hodgkin's disease. Histopathology. 1991 Jan;18(1):19–24. doi: 10.1111/j.1365-2559.1991.tb00809.x. [DOI] [PubMed] [Google Scholar]
  6. Brooks S. A., Leathem A. J. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J. 1995 Sep;27(9):689–693. [PubMed] [Google Scholar]
  7. Burroni D., Cintorino M., Leoncini L., Tosi P., Ceccarini C. Site-specific monoclonal antibodies against peanut agglutinin (PNA) from Arachis hypogaea. Immunohistochemical study of tissue-cultured cells and of 27 cases of Hodgkin's disease. Am J Pathol. 1988 May;131(2):351–360. [PMC free article] [PubMed] [Google Scholar]
  8. Campos L., Guyotat D., Archimbaud E., Devaux Y., Treille D., Larese A., Maupas J., Gentilhomme O., Ehrsam A., Fiere D. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol. 1989 Jun;72(2):161–166. doi: 10.1111/j.1365-2141.1989.tb07677.x. [DOI] [PubMed] [Google Scholar]
  9. Charalambous C., Singh N., Isaacson P. G. Immunohistochemical analysis of Hodgkin's disease using microwave heating. J Clin Pathol. 1993 Dec;46(12):1085–1088. doi: 10.1136/jcp.46.12.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Crocker J., Burnett D. Granulocyte markers in histopathology: a review. J Pathol. 1986 Oct;150(2):77–88. doi: 10.1002/path.1711500202. [DOI] [PubMed] [Google Scholar]
  11. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol. 1996 Aug;179(4):358–369. doi: 10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  12. Dorfman R. F., Gatter K. C., Pulford K. A., Mason D. Y. An evaluation of the utility of anti-granulocyte and anti-leukocyte monoclonal antibodies in the diagnosis of Hodgkin's disease. Am J Pathol. 1986 Jun;123(3):508–519. [PMC free article] [PubMed] [Google Scholar]
  13. Ellis P. A., Hart D. N., Colls B. M., Nimmo J. C., MacDonald J. E., Angus H. B. Hodgkin's cells express a novel pattern of adhesion molecules. Clin Exp Immunol. 1992 Oct;90(1):117–123. doi: 10.1111/j.1365-2249.1992.tb05842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Enblad G., Sundström C., Glimelius B. Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome. Histopathology. 1993 Jun;22(6):535–541. doi: 10.1111/j.1365-2559.1993.tb00173.x. [DOI] [PubMed] [Google Scholar]
  15. Ernst C. S., Shen J. W., Litwin S., Herlyn M., Koprowski H., Sears H. F. Multiparameter evaluation of the expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J Natl Cancer Inst. 1986 Aug;77(2):387–395. [PubMed] [Google Scholar]
  16. Frizzera G. The distinction of Hodgkin's disease from anaplastic large cell lymphoma. Semin Diagn Pathol. 1992 Nov;9(4):291–296. [PubMed] [Google Scholar]
  17. Georgii A., Fischer R., Hübner K., Schwarze E. W., Bernhards J. Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial. Leuk Lymphoma. 1993 Mar;9(4-5):365–370. doi: 10.3109/10428199309148535. [DOI] [PubMed] [Google Scholar]
  18. Hall P. A., D'Ardenne A. J. Value of CD15 immunostaining in diagnosing Hodgkin's disease: a review of published literature. J Clin Pathol. 1987 Nov;40(11):1298–1304. doi: 10.1136/jcp.40.11.1298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hanjan S. N., Kearney J. F., Cooper M. D. A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells. Clin Immunol Immunopathol. 1982 May;23(2):172–188. doi: 10.1016/0090-1229(82)90106-4. [DOI] [PubMed] [Google Scholar]
  20. Hansmann M. L., Zwingers T., Böske A., Löffler H., Lennert K. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol. 1984;108(3):321–330. doi: 10.1007/BF00390466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hoff S. D., Irimura T., Matsushita Y., Ota D. M., Cleary K. R., Hakomori S. Metastatic potential of colon carcinoma. Expression of ABO/Lewis-related antigens. Arch Surg. 1990 Feb;125(2):206–209. doi: 10.1001/archsurg.1990.01410140084013. [DOI] [PubMed] [Google Scholar]
  22. Hołowiecki J., Lutz D., Krzemień S., Schranz V., Jagoda K., Hołowiecka B., Graf F., Kelenyi G., Callea V., Brugiatelli M. The expression of CD 15 antigen on myeloid leukaemia cells--a new prognostic index for complete remission and for survival. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(2):289–295. [PubMed] [Google Scholar]
  23. Hsu S. M., Jaffe E. S. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol. 1984 Jul;82(1):29–32. doi: 10.1093/ajcp/82.1.29. [DOI] [PubMed] [Google Scholar]
  24. Lauritzen A. F., Ralfkiaer E. Use of monoclonal antibodies for the typing of malignant lymphomas in routinely processed biopsy samples. APMIS. 1991 Jul;99(7):631–639. doi: 10.1111/j.1699-0463.1991.tb01238.x. [DOI] [PubMed] [Google Scholar]
  25. LeBrun D. P., Kamel O. W., Dorfman R. F., Warnke R. A. Enhanced staining for Leu M1 (CD15) in Hodgkin's disease using a secondary antibody specific for immunoglobulin M. Am J Clin Pathol. 1992 Jan;97(1):135–138. doi: 10.1093/ajcp/97.1.135. [DOI] [PubMed] [Google Scholar]
  26. Leoncini L., Del Vecchio M. T., Kraft R., Megha T., Barbini P., Cevenini G., Poggi S., Pileri S., Tosi P., Cottier H. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol. 1990 Nov;137(5):1047–1057. [PMC free article] [PubMed] [Google Scholar]
  27. Loeffler M., Pfreundschuh M., Rühl U., Hiller E., Gerhartz H., Roloff R., Adler M., Schoppe W., Hagen-Aukamp U., Schmitt G. Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives. Recent Results Cancer Res. 1989;117:142–162. doi: 10.1007/978-3-642-83781-4_15. [DOI] [PubMed] [Google Scholar]
  28. Medeiros L. J., Weiss L. M., Warnke R. A., Dorfman R. F. Utility of combining antigranulocyte with antileukocyte antibodies in differentiating Hodgkin's disease from non-Hodgkin's lymphoma. Cancer. 1988 Dec 15;62(12):2475–2481. doi: 10.1002/1097-0142(19881215)62:12<2475::aid-cncr2820621204>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  29. Meis J. M., Osborne B. M., Butler J. J. A comparative marker study of large cell lymphoma, Hodgkin's disease, and true histiocytic lymphoma in paraffin-embedded tissue. Am J Clin Pathol. 1986 Nov;86(5):591–599. doi: 10.1093/ajcp/86.5.591. [DOI] [PubMed] [Google Scholar]
  30. Miyake M., Taki T., Hitomi S., Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med. 1992 Jul 2;327(1):14–18. doi: 10.1056/NEJM199207023270103. [DOI] [PubMed] [Google Scholar]
  31. Neuhold N., Längle F., Gnant M., Hollenstein U., Niederle B. Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. J Cancer Res Clin Oncol. 1992;118(8):629–634. doi: 10.1007/BF01211810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Parham D. M., Morton K., Coghill G., Robertson A. J., Kerr M. A. Expression of CD15 antigen in urinary bladder transitional cell carcinoma. J Clin Pathol. 1990 Jul;43(7):541–543. doi: 10.1136/jcp.43.7.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Petrella T., Michiels J. F., Michiels R., Collin F., Nabholtz J. M., Friedman S., Fargeot P. CD 15 antigen in Hodgkin's disease. Pathol Res Pract. 1989 Dec;185(6):886–890. doi: 10.1016/S0344-0338(89)80291-2. [DOI] [PubMed] [Google Scholar]
  34. Ree H. J., Neiman R. S., Martin A. W., Dallenbach F., Stein H. Paraffin section markers for Reed-Sternberg cells. A comparative study of peanut agglutinin, Leu-M1, LN-2, and Ber-H2. Cancer. 1989 May 15;63(10):2030–2036. doi: 10.1002/1097-0142(19890515)63:10<2030::aid-cncr2820631027>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  35. Said J. W. The immunohistochemistry of Hodgkin's disease. Semin Diagn Pathol. 1992 Nov;9(4):265–271. [PubMed] [Google Scholar]
  36. Sarker A. B., Akagi T., Jeon H. J., Miyake K., Murakami I., Yoshino T., Takahashi K., Nose S. Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30). Am J Pathol. 1992 Jul;141(1):19–23. [PMC free article] [PubMed] [Google Scholar]
  37. Schmid C., Pan L., Diss T., Isaacson P. G. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991 Oct;139(4):701–707. [PMC free article] [PubMed] [Google Scholar]
  38. Schröder S., Dralle H., Bay V., Böcker W. Immunhistologie und Prognose beim Schilddrüsenkarzinom. Bestimmung des Malignitätspotentials papillärer und medullärer Neoplasien durch S-100-Protein- und Leu-M1-Antigen-Nachweis. Acta Med Austriaca. 1989;16(1):2–5. [PubMed] [Google Scholar]
  39. Schröder S., Schwarz W., Rehpenning W., Dralle H., Bay V., Böcker W. Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland. J Cancer Res Clin Oncol. 1988;114(3):291–296. doi: 10.1007/BF00405836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schwarzinger I., Valent P., Köller U., Marosi C., Schneider B., Haas O., Knapp W., Lechner K., Bettelheim P. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol. 1990 Mar;8(3):423–430. doi: 10.1200/JCO.1990.8.3.423. [DOI] [PubMed] [Google Scholar]
  41. Sewell H. F., Jaffray B., Thompson W. D. Reaction of monoclonal anti Leu M1--a myelomonocytic marker (CD15)--with normal and neoplastic epithelia. J Pathol. 1987 Apr;151(4):279–284. doi: 10.1002/path.1711510407. [DOI] [PubMed] [Google Scholar]
  42. Sheibani K., Battifora H., Burke J. S., Rappaport H. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol. 1986 Apr;10(4):227–236. doi: 10.1097/00000478-198604000-00001. [DOI] [PubMed] [Google Scholar]
  43. Tamaru J., Mikata A., Azuma K., Takagi T. Reciprocal/dichotomic expression of vimentin and B cell differentiation antigens in Reed-Sternberg's cells. Virchows Arch A Pathol Anat Histopathol. 1990;416(3):213–220. doi: 10.1007/BF01678980. [DOI] [PubMed] [Google Scholar]
  44. Thomas X., Campos L., Archimbaud E., Shi Z. H., Treille-Ritouet D., Anglaret B., Fiere D. Surface marker expression in acute myeloid leukaemia at first relapse. Br J Haematol. 1992 May;81(1):40–44. doi: 10.1111/j.1365-2141.1992.tb08168.x. [DOI] [PubMed] [Google Scholar]
  45. Torii A., Nakayama A., Harada A., Nakao A., Nonami T., Sakamoto J., Watanabe T., Ito M., Takagi H. Expression of the CD15 antigen in hepatocellular carcinoma. Cancer. 1993 Jun 15;71(12):3864–3867. doi: 10.1002/1097-0142(19930615)71:12<3864::aid-cncr2820711212>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  46. Werner M., Georgii A., Bernhards J., Hübner K., Schwarze E. W., Fischer R. Characterization of giant cells in Hodgkin's lymphomas by immunohistochemistry applied to randomly collected diagnostic biopsies from the German Hodgkin Trial. Hematol Oncol. 1990 Sep-Oct;8(5):241–250. doi: 10.1002/hon.2900080502. [DOI] [PubMed] [Google Scholar]
  47. Wieczorek R., Buck D., Bindl J., Knowles D. M. Monoclonal antibody Leu-22 (L60) permits the demonstration of some neoplastic T cells in routinely fixed and paraffin-embedded tissue sections. Hum Pathol. 1988 Dec;19(12):1434–1443. doi: 10.1016/s0046-8177(88)80236-3. [DOI] [PubMed] [Google Scholar]
  48. Zarate-Osorno A., Roman L. N., Kingma D. W., Meneses-Garcia A., Jaffe E. S. Hodgkin's disease in Mexico. Prevalence of Epstein-Barr virus sequences and correlations with histologic subtype. Cancer. 1995 Mar 15;75(6):1360–1366. doi: 10.1002/1097-0142(19950315)75:6<1360::aid-cncr2820750619>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  49. de Mascarel I., Trojani M., Eghbali H., Coindre J. M., Bonichon F. Prognostic value of phenotyping by Ber-H2, Leu-M1, EMA in Hodgkin's disease. Arch Pathol Lab Med. 1990 Sep;114(9):953–955. [PubMed] [Google Scholar]
  50. von Wasielewski R., Werner M., Fischer R., Hansmann M. L., Hübner K., Hasenclever D., Franklin J., Sextro M., Diehl V., Georgii A. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol. 1997 Mar;150(3):793–803. [PMC free article] [PubMed] [Google Scholar]
  51. von Wasielewski R., Werner M., Nolte M., Wilkens L., Georgii A. Effects of antigen retrieval by microwave heating in formalin-fixed tissue sections on a broad panel of antibodies. Histochemistry. 1994 Sep;102(3):165–172. doi: 10.1007/BF00268892. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES